Anastasia Chrysostomou, Eugenia Pedagogos, Lachlan MacGregor, and Gavin J. Becker

Transcription

1 Original Articles Double-Blind, Placebo-Controlled Study on the Effect of the Aldosterone Receptor Antagonist Spironolactone in Patients Who Have Persistent Proteinuria and Are on Long-Term Angiotensin-Converting Enzyme Inhibitor Therapy, with or without an Angiotensin II Receptor Blocker Anastasia Chrysostomou, Eugenia Pedagogos, Lachlan MacGregor, and Gavin J. Becker Royal Melbourne Hospital, Parkville, Victoria, Australia Studies have shown that dual therapy with angiotensin-converting enzyme inhibitors (ACEI) and either angiotensin II receptor blockers or aldosterone receptor antagonists is more effective in reducing proteinuria than either agent used alone. The questions that remain are as follows: (1) Which of these agents should be used as dual therapy with the ACEI? (2) Does a higher level of blockade of the renin-angiotensin-aldosterone system with triple therapy offer an advantage over dual blockade? A 3-mo randomized, double-blind, placebo-controlled study was performed in 41 patients with proteinuria >1.5 g/d. Four treatment groups were compared: (1) Ramipril spironolactone placebo irbesartan placebo, (2) ramipril irbesartan spironolactone placebo, (3) ramipril irbesartan placebo spironolactone, and (4) ramipril irbesartan spironolactone. The percentage change in protein excretion differed according to treatment arm (ANOVA: F 3,35 8.6, P < 0.001). Pair-wise comparison showed that greater reduction in protein excretion occurred in treatment regimens that incorporated spironolactone. The reduction in proteinuria at 3 mo was as follows: Group 1, 1.4%; group 2, 15.7%; group 3, 42.0%; and group 4, 48.2%. The reduction in proteinuria among patients who were taking spironolactone-containing regimens was sustained at 6 and 12 mo. This study suggests that aldosterone receptor blockade offers a valuable adjuvant treatment when used with ACEI therapy for the reduction of proteinuria. Results suggest no advantage of triple blockade over dual blockade of the renin-angiotensin-aldosterone system to reduce proteinuria. Clin J Am Soc Nephrol 1: , doi: /CJN The number of patients who present with ESRD that requires hemodialysis or transplantation is increasing, highlighting the need to find strategies that slow progression of kidney disease. The need for these strategies is even more critical in countries in which dialysis in not a treatment option. Ideally, new treatment strategies should be readily accessible and not financially prohibitive. The importance of proteinuria as a significant risk factor for ESRD is increasingly recognized (1), and treatment that is targeted at reducing proteinuria has been shown to reduce progression of renal disease (2 7). Numerous clinical trials have established that interruption of the renin-angiotensin-aldosterone system (RAAS) cascade with angiotensin-converting enzyme inhibitors (ACEI) (2,3) or angiotensin receptor blockers (ARB) (4) is beneficial in slowing progression of renal disease. However, the use of these agents Received September 15, Accepted January 3, Published online ahead of print. Publication date available at Address correspondence to: Dr. Anastasia Chrysostomou, Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria 3052, Australia. Phone: ; Fax: ; anastasiac@optusnet.com.au has limitations, with significant numbers of treated patients still demonstrating progressive renal disease (2,5). Several studies have raised the possibility that aldosterone has a role in mediating renal damage (8,9). Although it may be anticipated that using ACE or ARB would prevent any aldosterone-mediated effects, this does not seem to be the case. In 2001, we reported an uncontrolled study in which we treated eight patients who had chronic kidney disease and persistent proteinuria with the aldosterone receptor antagonist spironolactone in addition to ACE therapy and demonstrated a 54% reduction in proteinuria after 4 wk of treatment (10). Since then, others have confirmed the effectiveness of aldosterone receptor blockade in reducing proteinuria (11 16). Studies have shown that dual therapy with ACE and ARB (6) or ACE with aldosterone receptor antagonists (12,15) is more effective in reducing proteinuria than either agent used alone. With regard to the lowering of proteinuria, we wished to address the following questions: (1) Is angiotensin receptor blockade or aldosterone receptor antagonism more effective in combination with ACE inhibition? (2) Does a higher level of blockade of the RAAS with triple therapy offer an advantage over dual blockade? Copyright 2006 by the American Society of Nephrology ISSN: /

2 Clin J Am Soc Nephrol 1: , 2006 Spironolactone to Reduce Proteinuria 257 Materials and Methods Between January 2002 and September 2004, patients who were seen in the Nephrology Department of the Royal Melbourne Hospital were screened for the study. Inclusion criteria were (1) age 18 to 75 yr, (2) 24-h urinary protein excretion that exceeded 1.5 g/24 h on at least two occasions at least 3 mo apart, (3) serum creatinine level 200 mol/l with 20% variability in the preceding 3 mo, and (4) treatment with an ACE for at least 6 mo. Exclusion criteria were (1) diastolic BP (DBP) 115 mmhg or systolic BP (SBP) 220 mmhg; (2) serum potassium level 5.0 mm/l; (3) serum bicarbonate level 20 mmol/l; (4) acute myocardial infarction or stroke in the previous 6 mo; (5) treatment with corticosteroids, nonsteroidal anti-inflammatory drugs, or immunosuppressant drugs; and (6) evidence or suspicion of renovascular disease, obstructive uropathy, collagen disease, cancer, drug or alcohol abuse, pregnancy, breastfeeding, or ineffective contraception. Study Design The study was a single-center, double-blind, placebo-controlled, randomized intervention trial that comprised a run-in phase, a compliance phase, and a treatment phase (Figure 1). Three months after randomization, the patient codes were opened. All patients remained on the allocated treatment until 6 mo and were given the option to start spironolactone. Treatment was continued on an open-label basis until 12 mo. The Melbourne Health Human Ethics committee approved the protocol, and all participants gave written informed consent. This study was investigator initiated and entirely internally funded. The randomization process was undertaken by the Royal Melbourne Hospital Pharmacy Department. Treatment assignment was by simple randomization. Clinical trial pharmacists, who were otherwise not involved in the clinical trial, performed treatment allocation. After screening, all eligible patients entered a run-in phase to ensure that they were treated similarly before the commencement of the trial. During this phase, all participants were changed to the oral ACE ramipril 10 mg/d, and DBP was treated to 90 mmhg. Once participants had been Figure 1. Study design. ACEI, angiotensin-converting enzyme inhibitor. on ramipril 10 mg/d for at least 1 mo and achieved the target DBP, they entered a 3-wk compliance phase to ensure that they took medications prescribed. During the compliance phase, the ramipril dose was reduced from 10 to 5 mg/d, and participants were given two placebo medications to be taken with their morning ramipril dose. They also were given dietary advice about reduced sodium intake, reduced potassium intake, and protein restriction (0.6 to 0.8 g protein/kg body wt per 24 h). Compliance was assessed by pill count. Participants then were randomized to one of four treatment groups for 12 wk: (1) group 1, ramipril, irbesartan placebo, and spironolactone placebo; (2) group 2, ramipril, irbesartan, and spironolactone placebo; (3) group 3, ramipril, irbesartan placebo, and spironolactone; or (4) group 4, ramipril, irbesartan, and spironolactone. The commencing dosages were ramipril 5 mg/d, irbesartan 150 mg/d, and spironolactone 25 mg/d; these doses were maintained for the duration of the study unless hyperkalemia occurred. The target DBP of 90 mmhg was maintained during the compliance and treatment phases with BP-lowering agents other than ACEI, ARB, spironolactone, or nondihydropyridine calcium antagonists. When serum potassium rose to 6.0 mmol/l, diuretic therapy was commenced or dosage was increased, the dosage of ramipril was reduced, or the dosage of spironolactone or spironolactone placebo was reduced to 25 mg alternate days. Twenty-four-hour urinary protein excretion and Cockcroft-Gault calculated creatinine clearance were measured at the beginning and the end of the compliance phase, at the end of the 12-wk treatment phase, and at 6 and 12 mo. BP; body weight; and serum potassium, bicarbonate, urea, and creatinine levels were measured at the beginning and the end of the compliance phase and every 4 wk during the treatment phase, then every 3 mo thereafter. Serum potassium was measured 1 wk after the treatment phase was started. Statistical Analyses The primary study end point was the between-group difference in percentage reduction in 24-h urinary protein excretion after 3 mo of treatment. Secondary end points included (1) between-group difference at 6 mo, (2) percentage reduction of 24-h urine protein excretion at 3 and 6 mo separately for each group, and (3) changes in BP and Cockcroft-Gault calculated creatinine clearance. Safety data that were collected included weight and serum potassium, bicarbonate, urea, and creatinine. A post hoc analysis included comparison in the percentage reduction in protein excretion at 6 and 12 mo among patients who received spironolactone. On the basis of the results of our pilot study (10), in which spironolactone resulted in an average reduction in 24-h urinary protein excretion of 54% after 1 mo of treatment, we estimated that nine participants were required in each treatment group. This sample size was calculated to achieve 80% power to detect a 35% difference in 24-h urinary protein excretion as a result of the addition of either spironolactone or irbesartan to ramipril compared with ramipril alone, at a 5% level. All analyses at 3 and 6 mo were based on the intention-to-treat principle. Analyses at 12 mo were according to treatment received. Data from all randomly assigned participants were included, with the exception of one participant who ceased treatment within the first week of randomization on whom no follow-up data were available. ANOVA was used for between-group comparison at each time point (3 and 6 mo). When ANOVA provided evidence of between-group difference, pair-wise comparisons were made using the two-sample t test with Bonferroni-adjusted P values. Creatinine clearance values were logtransformed. Within each group, the change in protein excretion between baseline and 3 mo and between baseline and 6 mo was tested using a one-sample t test. Baseline characteristics were compared using

3 258 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 1: , 2006 Table 1. Baseline characteristics at the start of the treatment phase a Group 1 Group 2 Group 3 Group 4 P Value n Age (yr; range) 59.2 (10.1); 35 to (8.8); 44 to (8.8); 46 to (15.4); 24 to Gender (male/female) 7/3 8/2 7/3 6/ h urinary protein (g/d; range) 2.6 (1.6); 1.2 to (1.8); 1.5 to (1.4); 1.2 to (1.9); 1.2 to SBP (mmhg; range) (19.5); 110 to (11.4); 120 to (12.9); 120 to (10.2); 120 to DBP (mmhg; range) 79.5 (8.6); 70 to (9.0); 60 to (10.5); 55 to (6.1); 65 to Mean BP (mmhg; range) 97.3 (11.4); 83.3 to (7.1); 86.6 to (8.8); 83.3 to (4.7); 86.6 to Diagnosis diabetic nephropathy glomerulonephritis interstitial nephropathy other b a Group 1, ramipril, placebo (irbesartan), and placebo (spironolactone); group 2, ramipril, irbesartan, and placebo (spironolactone); group 3, ramipril, placebo (irbesartan), and spironolactone; group 4, ramipril, irbesartan, and spironolactone. Data are mean (SD). DBP, diastolic BP; SBP, systolic BP. b Reflux nephropathy (group 2) and cholesterol emboli (group 3). ANOVA (continuous data) or the 2 test of homogeneity (gender). Statistical analysis was performed using Stata 7.0 (17). Results Compliance Phase Protein excretion remained at a stable level overall during the 3-wk compliance phase. The mean change overall was 2.04% (95% confidence interval to 5.98%). No significant changes were seen in BP, body weight, serum electrolytes, or renal function during the compliance phase. Compliance as assessed by pill count was 100% for all participants. Baseline Characteristics Baseline characteristics were similar across all treatment arms (Table 1). Treatment Effects 24-H Urinary Protein Excretion. The percentage change in 24-h urinary protein excretion at 3 and 6 mo is shown in Figure 2 and Table 2. Between-Group Analysis. At 3 mo, the percentage change in protein excretion at 3 mo differed according to treatment group. (F 3,35 8.6, P 0.001). Pair-wise comparisons showed that the greatest reduction occurred among patients who were given spironolactone. Compared with the ramipril group (group 1), the 24-h urinary protein excretion reduction at the end of the 3-mo treatment was greater in the ramipril and spironolactone group (group 3; P 0.004) and in the ramipril, irbesartan, and spironolactone group (group 4; P 0.001) but not in the ramipril and irbesartan group (group 2; P 1.000). Triple therapy offered no advantage to using dual therapy with ramipril and spironolactone, resulting in only an additional 6% reduction in protein excretion. Alternatively, using triple therapy provided an additional 32% change in the reduction of proteinuria compared with the dual therapy of ramipril and irbesartan. These results suggest that among patients who were Figure 2. Percentage change in 24-h urine protein excretion compared with baseline at 3 and 6 mo by treatment group.

4 Clin J Am Soc Nephrol 1: , 2006 Spironolactone to Reduce Proteinuria 259 Table 2. Effect of treatment on BP, 24-h urinary creatinine clearance, proteinuria, and safety data a Parameter Time Group 1 Group 2 Group 3 Group 4 ANOVA: P Value F Statistic (D,F) % change proteinuria Month Month ( 16.7 to 13.9) 15.7 ( 35.2 to 3.8) 42.0 ( 60.1 to 25.5) 48.2 ( 60.3 to 33.3) 8.6 (3,35) Month ( 38.5 to 40.1) 11.1 ( 35.9 to 13.7) 48.4 ( 67.9 to 29.1) 51.8 ( 63.1 to 29.9) 4.94 (3,35) Creatinine clearance Month (48.7 to 114.4) 68.0 (41.7 to 94.3) 59.4 (47.3 to 71.4) 57.6 (41.3 to 73.9) 0.62 (3,37) (ml/min) Month (46.9 to 122.0) 67.4 (40.6 to 94.1) 54.3 (43.7 to 64.9) 56.5 (38.6 to 74.4) 0.89 (3,37) Month (43.3 to 121.6) 65.2 (37.4 to 93.0) 56.2 (45.7 to 66.8) 59.7 (43.0 to 76.4) 0.85 (3,36) SBP (mmhg) Month (119.1 to 146.9) (123.9 to 140.1) (131.8 to 150.2) (123.1 to 136.9) 1.25 (3,38) Month (116.9 to 139.1) (124.0 to 139.0) (119.0 to 150.0) (117.1 to 142.0) 0.24 (3,36) Month (122.2 to 142.8) (115.6 to 131.4) (121.4 to 147.6) (116.9 to 135.9) 1.07 (3,35) DBP (mmhg) Month (73.3 to 85.7) 79.5 (73.1 to 85.9) 76.0 (68.5 to 83.5) 75.5 (71.4 to 79.6) 1.07 (3,35) Month (66.5 to 82.5) 76.0 (72.7 to 79.3) 73.0 (66.9 to 79.1) 76.4 (71.1 to 81.6) 0.21 (3,38) Month (75.6 to 88.4) 72.0 (66.4 to 77.6) 76.5 (69.3 to 83.7) 72.7 (68.1 to 77.3) 2.94 (3,35) Serum potassium Month (4.2 to 4.5) 4.5 (4.3 to 4.6) 4.5(4.0 to 4.8) 4.8 (4.5 to 5.0) 2.09 (3,38) (mmol/l) Month (3.9 to 4.5) 4.5 (4.2 to 4.7) 4.9 (4.4 to 5.2) 4.8 (4.3 to 5.2) 2.79 (3,36) Month (4.0 to 4.6) 4.7 (4.4 to 5.0) 4.9 (4.3 to 5.3) 4.9 (4.3 to 5.4) 2.71 (3,35) Serum creatinine Month (0.10 to 0.13) 0.13 (0.10 to 0.17) 0.14 (0.11 to 0.18) 0.15 (0.11 to 0.2) 1.42 (3,37) (mmol/l) Month (0.9 to 0.13) 0.14 (0.16 to 0.10) 0.15 (0.12 to 0.19) 0.17 (0.11 to 0.23) 1.94 (3,36) Month (0.10 to 0.14) 0.15 (0.10 to 0.19) 0.15 (0.11 to 0.19) 0.16 (0.10 to 0.21) 0.99 (3,35) a Group 1, ramipril, placebo (irbesartan), and placebo (spironolactone); group 2, ramipril, irbesartan, and placebo (spironolactone); group 3, ramipril, placebo (irbesartan), and spironolactone; group 4, ramipril, irbesartan, and spironolactone. Data are mean (95% confidence intervals).

5 260 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 1: , 2006 on the spironolactone-containing regimen, there was no advantage to using triple therapy. At 6 mo, again, the percentage change in protein excretion differed according to treatment (F 3, , P 0.005). Pairwise comparisons showed that the greatest reduction occurred among patients who were given spironolactone (Table 3). At 12 mo, five of 10 patients in groups 1 and three of 10 patients of group 2 had been started on spironolactone. Analysis of the data was according to treatment received. Of patients who were randomly assigned to groups 1 and 2 and subsequently had spironolactone added, the percentage reduction in 24-h urine protein excretion compared with 6 mo was 42.1 (range 61.2 to 29.0) and 37 (range 47 to 25), respectively. This compares with patients in groups 1 and 2 who continued on the randomized regimen: 7.9 (range 25.1 to 6.3) and 10 (range to 27.0 to 100), respectively. The percentage reduction of 24-h urine protein excretion at 12 mo compared with baseline was sustained for patients who were randomly assigned to the spironolactone-containing regimens: Groups 3 and 4, 44.8 ( 73.6 to 16.1) and 43.0 ( 62.0 to 24.7), respectively. Effect of Each Treatment Regimen. At the end of 3 mo of blinded therapy, the percentage reduction in 24-h urine protein excretion compared with baseline was significantly different from zero for the spironolactone-containing regimens: Group 3 (P 0.001) and group 4 (P 0.001). No significant reduction in proteinuria was seen for the non spironolactone-containing regimens: Group 1 (P 0.840) and group 2 (P 0.102). Again, at 6 mo, only the regimens that contained spironolactone significantly changed the percentage reduction in 24-h urine protein excretion (group 1 P 0.965; group 2 P 0.337; group 3 P 0.001; group 4 P 0.001). Cockcroft-Gault Calculated Creatinine Clearance. No evidence of differences in creatinine clearance was seen within or between the groups or between the groups at 3 and 6 mo (Table 2). BP. No evidence of differences was seen within the groups or between the groups in change in SBP at 3 and 6 mo. Similarly, the DBP was not different either within the groups or Table 3. Paired comparisons of percentage change in protein excretion at 3 and 6 mo a Group Comparisons 3Mo ANOVA P Value 6Mo 1 versus versus versus versus versus a Group 1, ramipril, placebo (irbesartan), and placebo (spironolactone); group 2, ramipril, irbesartan, and placebo (spironolactone); group 3, ramipril, placebo (irbesartan), and spironolactone; group 4, ramipril, irbesartan, and spironolactone. between the groups at 3 mo; however, at 6 mo, there was a difference between the groups with the DBP being higher in the ramipril only group (P 0.046; Table 2). Target DBP of 90 mmhg was achieved in all but one participant in the ramipril group. Effect of Diabetic Nephropathy. Twenty-seven (67%) of 41 patients had diabetic nephropathy (Table 1). There was no evidence of interaction between treatment effects at either 3 or 6 mo and cause of nephropathy (diabetic versus nondiabetic nephropathy; likelihood ratio test: 3 mo 2 (3) 1.65, P 0.649; 6mo 2 (3) 4.50, P 0.213). Estimated treatment effects were similar in patients with and without diabetes (Table 4). Co-Treatment. The distribution of additional BP-lowering drugs that were used to control BP was similar in all groups. They included diuretics, blockers, central agonists, peripheral antagonists, and dihydropyridine calcium antagonists. An average of 2.2, 1.9, 2.6, and 2.3 additional BP-lowering drugs were required in groups 1 through 4, respectively. The percentage of patients who were taking a thiazide or loop diuretic was not significantly different among groups 1 through 4: 70, 70, 90, and 70, respectively. Safety Data. One patient withdrew from the study after 1 wk of active therapy with ramipril, complaining of feeling unwell and light headed. There was no evidence of hypotension and no change in his renal function compared with baseline. Gynecomastia was not observed in any of the groups. There was no significant difference between treatment groups or within the treatment groups in the change in weight, serum bicarbonate, serum creatinine, serum urea, or serum cholesterol during the 3-, 6-, and 12-mo treatment periods. In participants with diabetes, no difference was seen for the change in HbA 1c during the 3- and 12-mo treatment periods between or within the treatment groups. The serum potassium was different at 3 mo between the groups (Table 2). The serum potassium was approximately 0.5 mmol/l higher in the spironolactone-containing regimens. A serum potassium of 6.0 mmol/l was seen in one patient in group 3 (ramipril spironolactone) and occurred at 2 mo and in two patients in group 4, one occurring at 3 mo and one occurring at 6 mo. The underlying renal disease was diabetic nephropathy, IgA nephropathy, and focal sclerosis and segmental hyalinosis, respectively. All responded to a reduction in ramipril dose and the introduction or increased dose of a diuretic. Serum bicarbonate decreased to 20 mmol/l in all three patients. Discussion It is generally accepted that lowering protein excretion is a desirable treatment goal in chronic proteinuric kidney disease (1,7). Treatment with drugs that interfere with the RAAS slows the course of chronic diabetic and nondiabetic disease (2,4,5). The renoprotective efficacy of these blocking agents may be related to their ability to reduce protein excretion. It was demonstrated recently that for each halving of proteinuria level between baseline and 12 mo with treatment, risk for end-stage renal failure was reduced by more than half (7). Our study indicates a potentially important role for spironolactone in

6 Clin J Am Soc Nephrol 1: , 2006 Spironolactone to Reduce Proteinuria 261 Table 4. Mean percentage change in urine protein excretion from baseline to 3 mo and from baseline to 6 mo by treatment group: Diabetic versus nondiabetic nephropathy a Diabetic Nephropathy Nondiabetic Nephropathy Group 3Mo 6Mo 3Mo 6Mo n % n % n % n % a Group 1, ramipril, placebo (irbesartan), and placebo (spironolactone); group 2, ramipril, irbesartan, and placebo (spironolactone); group 3, ramipril, placebo (irbesartan), and spironolactone; group 4, ramipril, irbesartan, and spironolactone. reducing proteinuria. ACEI initially causes a decrease in aldosterone concentration, but with prolonged use, this suppression is not sustained (18). This may be relevant to the dramatic effects seen in our study, in which all patients had already been taking ACEI for 6 mo and circulating aldosterone levels were presumably not suppressed. We have shown that the addition of the aldosterone receptor antagonist spironolactone to the ACE ramipril resulted in a 42.0% reduction in 24-h urinary protein excretion at 3 mo in patients with proteinuric chronic renal disease. The reduction in proteinuria was sustained up to 12 mo. There was no advantage to using triple blockade of the RAAS with ramipril, irbesartan, and spironolactone compared with dual therapy with ramipril and spironolactone. Triple therapy did offer an advantage to dual therapy with ramipril and irbesartan, suggesting that spironolactone targets a different mediator of disease. The dosages of ramipril, irbesartan, and spironolactone in this study were chosen to minimize the risk for hyperkalemia in patients who were randomly assigned to triple therapy and are not maximal. Our study does not address whether maximal doses of ACEI and angiotensin receptor antagonist would be as effective in lowering proteinuria as spironolactone-containing regimens; neither does our study address whether a higher dosage of spironolactone would result in an even greater fall in proteinuria. The effect does not seem to be related directly to BP changes; similarly, we could find no evidence that this related directly to reduction in creatinine clearance. Recently, there has been evidence to suggest that diuretics and low-salt diet may potentiate the effect of renin-aldosterone system blocking agents (19,20). More than 70% of patients in every group were taking either a loop diuretic or thiazide diuretic, so the effect of spironolactone in reducing proteinuria is over and above that provided by concurrent use of diuretics. Hyperkalemia is a potentially serious complication of combining spironolactone with ACE (21). The patients in our study were screened carefully for risk for developing hyperkalemia on combined treatment. All patients in this study had serum potassium measured 1 wk after starting the treatment phase and every 3 mo thereafter. Although hyperkalemia was not a clinical problem in our study, we do not advocate the use of combination treatment without such careful screening and ongoing monitoring of candidate patients. The COOPERATE study demonstrated that combination therapy with ACE and ARB was more effective in minimizing proteinuria and slowing progression of renal disease than either agent alone (6). Recent studies have demonstrated that combination therapy with ARB is more effective than the maximal recommended dosage of ACEI in reducing proteinuria in both patients both with and without diabetes (22,23). The effect of the combination therapy in our study was a 15.7% change in proteinuria. This is quantitatively comparable to that seen in other studies of combination therapy, in which changes in proteinuria ranging from 0 to 40% have been reported in randomized trials of adding angiotensin receptor antagonists to ACEI (24 27). However, it does not reach statistical significance because our study was specifically powered to demonstrate a 35% or greater difference. Adding spironolactone to ramipril was more effective than adding irbesartan, and, indeed, because reduction in ramipril dosage from 10 to 5 mg (Table 1) did not significantly alter protein excretion, it could be argued that adding spironolactone likely is more effective than increasing ramipril above the maximum recommended dose. This study has reinforced the importance of aldosterone as a mediator of renal disease. The use of spironolactone with an ACE alone or in combination with an ARB resulted in a significant reduction in proteinuria. There was no advantage to using triple blockade of the renin-angiotensin aldosterone system over dual blockade with spironolactone and ACEI. We have demonstrated that adding spironolactone to ACE therapy is an effective tool in the effort to lower proteinuria. However, proteinuria reduction remains a surrogate marker for long-term renal survival, and a larger study with longer follow-up is required to demonstrate whether the results shown in our study translate to improved renal survival in patients with persistent proteinuria. Acknowledgments This study was presented in abstract form at the World Congress of Nephrology meeting, Singapore, June 26 to 30, We gratefully acknowledge the provision of ramipril at no cost by

7 262 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 1: , 2006 Sonofi-Aventis and the cooperation of the Royal Melbourne Hospital Department of Nephrology clinic staff in this study. References 1. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA: Management of glomerular proteinuria: A commentary. J Am Soc Nephrol 14: , The GISEN Study Group: Randomized placebo-controlled trial of the effect of ramipril on decline on GFR and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group. Lancet 349: , Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: , Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: , Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolesem M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: , Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-ii receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361: , Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45: , Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: , Quan ZY, Walser M, Hill GS: Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 41: , Chrysostomou A, Becker G: Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345: , Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41: 64 68, Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, Ravid M: The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study. Diabet Med 21: , Epstein M, Buckalew V, Martinez F: Eplerenone reduces proteinuria in type 2 diabetes mellitus [Abstract]. J Am Coll Cardiol 39: 249, Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18: 44 49, Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 28: , Bianchi S, Bigazzi R, Campese VM: Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis 46: 45 51, StataCorp: Stata Statistical Software: Release 7.0, College Station, TX, Stata Corporation 18. Pitt B: Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drugs Ther 9: , Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13: , Esnault VL, Ekhlas A, Delcroix C, Moutel MG, Nguyen JM: Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 16: , Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH: Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: Analysis of 44 cases. BMJ 327: , Kincaid-Smith P, Fairley KF, Packham D: Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: Effects on proteinuria and blood pressure. Nephrol Dial Transplant 19: , Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63: , Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62: , Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17: , Kincaid-Smith P, Fairley K, Packham D: Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 17: , Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 67: , 2005